Inhibition of the inflammatory response to antigen challenge in the hamster cheek pouch by the tachykinin NK1 receptor antagonist SR140333

被引：0
|
作者：
Hall, JM
Palframan, R
Reynia, S
Brain, SD
机构：
[1] UNIV LONDON,UNIV LONDON KINGS COLL,DIV BIOMED SCI,PHARMACOL GRP,LONDON SW3 6LX,ENGLAND
[2] UNIV SURREY,SCH BIOL SCI,GUILDFORD GU2 5XH,SURREY,ENGLAND
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 1996年 / 119卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P274 / P274
页数：1
相关论文
共 50 条
  • [31] Antitussive activity of the tachykinin NK1 receptor antagonist, CP-99994, in dogs
    Chapman, RW
    House, A
    Liu, F
    Celly, C
    Mei, H
    Hey, JA
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 485 (1-3) : 329 - 332
  • [32] Effect of single point mutations of the human tachykinin NK1 receptor on antagonist affinity
    Hawcock, AB
    Lundstrom, K
    Thomas, P
    Naylor, A
    BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 : P328 - P328
  • [33] PHARMACOLOGY OF CP-99,994 - A NONPEPTIDE ANTAGONIST OF THE TACHYKININ NK1 RECEPTOR
    MCLEAN, S
    GANONG, A
    SEYMOUR, PA
    SNIDER, RM
    DESAI, MC
    ROSEN, T
    BRYCE, DK
    LONGO, KP
    REYNOLDS, LS
    ROBINSON, G
    SCHMIDT, AW
    SIOK, C
    HEYM, J
    REGULATORY PEPTIDES, 1992, : S120 - S120
  • [34] Effect of single point mutations of the human tachykinin NK1 receptor on antagonist affinity
    Lundstrom, K
    Hawcock, AB
    Vargas, A
    Ward, P
    Thomas, P
    Naylor, A
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 337 (01) : 73 - 81
  • [35] Inhibition of inflammatory cell recruitment by the tachykinin NK3-receptor antagonist, SR 142801, in a murine model of asthma
    Nénan, S
    Germain, N
    Lagente, V
    Emonds-Alt, X
    Advenier, C
    Boichot, E
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 421 (03) : 201 - 205
  • [36] Inhibition of the recruitment of inflammatory cells by the tachykinin NK3 receptor antagonist, SR 142801, in a murine model of asthma
    Nenan, S.
    Germain, N.
    Lagente, V.
    Emonds-Alt, X.
    Advenier, C.
    Boichot, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 : 118 - 118
  • [37] PHARMACOLOGY OF GR203040, A POTENT AND SELECTIVE NONPEPTIDE TACHYKININ NK1 RECEPTOR ANTAGONIST
    BEATTIE, DT
    CONNER, HE
    HAWCOCK, AB
    PERREN, MJ
    WARD, P
    BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 : P37 - P37
  • [38] Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK1 receptor antagonist
    Cascieri, MA
    Ber, E
    Fong, TM
    Hale, JJ
    Tang, F
    Shiao, LL
    Mills, SG
    MacCoss, M
    Sadowski, S
    Tota, MR
    Strader, CD
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 325 (2-3) : 253 - 261
  • [39] SCH 206272:: a potent, orally active tachykinin NK1, NK2, and NK3 receptor antagonist
    Anthes, JC
    Chapman, RW
    Richard, C
    Eckel, S
    Corboz, M
    Hey, JA
    Fernandez, X
    Greenfeder, S
    McLeod, R
    Sehring, S
    Rizzo, C
    Crawley, Y
    Shih, NY
    Piwinski, J
    Reichard, G
    Ting, P
    Carruthers, N
    Cuss, FM
    Billah, M
    Kreutner, W
    Egan, RW
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 450 (02) : 191 - 202
  • [40] Two affinities for a single antagonist at the neuronal NK1 tachykinin receptor:: evidence from quantitation of receptor endocytosis
    Jenkinson, KM
    Southwell, BR
    Furness, JB
    BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (01) : 131 - 136
12345